DOCSLIB.ORG

Effect of First-Line Endocrine Therapy in Patients with Hormone-Sensitive Advanced Breast Cancer: a Network Meta-Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of First-Line Endocrine Therapy in Patients with Hormone-Sensitive Advanced Breast Cancer: a Network Meta-Analysis Journal name: OncoTargets and Therapy Article Designation: Original Research Year: 2018 Volume: 11 OncoTargets and Therapy Dovepress Running head verso: Zhang et al Running head recto: Effect of first-line endocrine therapy in advanced breast cancer open access to scientific and medical research DOI: 165681 Open Access Full Text Article ORIGINAL RESEARCH Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis Tingting Zhang1 Background: Endocrine therapy is the cornerstone treatment for patients with hormone Fubin Feng2 receptor-positive advanced breast cancer. We aimed to assess the effectiveness of various Wenge Zhao3 first-line endocrine monotherapies or combinations to determine the optimal sequence in a Jinhui Tian4 network meta-analysis. Yan Yao3 Materials and methods: We searched PubMed, EMBASE, and the Cochrane Library for Chao Zhou2 randomized controlled trials (RCTs) from inception up to November 21, 2017. We included only RCTs that assessed the effectiveness of the following treatments as a monotherapy or in Shengjie Dong5 combination as the first-line treatment: tamoxifen, anastrozole, letrozole, exemestane, fulves- Congcong Wang6 trant, palbociclib, and ribociclib. The results were presented with pooled odds ratio or hazard Chuanxin Zang1 For personal use only. ratio (HR), and 95% credible interval (CrI). The primary outcomes were objective response 7 Qingliang Lv rate (ORR) and progression-free survival/time to progression. 2,8 Changgang Sun Results: A total of 16 eligible articles (14 RCTs) involving 6,602 patients treated with 10 dif- 1College of Traditional Chinese ferent first-line endocrine therapies were assessed in our network meta-analysis. Palbociclib plus Medicine, Shandong University letrozole was superior to anastrozole, letrozole, exemestane, fulvestrant 500 mg, and anastrozole of Traditional Chinese Medicine, WeiFang, China; 2Department of plus fulvestrant (loading dose) (HR=0.44, 95% CrI: 0.33–0.58; HR=0.56, 95% CrI: 0.45–0.68; Oncology, Weifang Traditional Chinese HR=0.45, 95% CrI: 0.32–0.61; HR=0.58, 95% CrI: 0.42–0.81; HR=0.50, 95% CrI: 0.37–0.68; 3 Hospital, WeiFang, China; Department respectively). However, there is no significant advantage compared with ribociclib plus letrozole of Oncology, Clinical Medical Colleges, Weifang Medical University, (HR=1.00, 95% CrI: 0.72–1.39). In terms of ORR, ribociclib plus letrozole is more effective WeiFang, China; 4Evidence-Based than palbociclib plus letrozole (odds ratio=1.30, 95% CrI: 0.83–2.02). Medicine Center, School of Basic Palbociclib plus letrozole and ribociclib plus letrozole might be the optimal first- Medical Sciences, Lanzhou University, Conclusion: OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 08-Dec-2018 Lanzhou, China; 5Department of the line endocrine therapeutic choices for hormone receptor-positive/human epidermal growth factor Joint and Bone Surgery, Yantaishan receptor 2-negative advanced breast cancer due to a longer progression-free survival/time to Hospital, Yantai, China; 6Department of Oncology, Zibo Maternal and progression and a more efficacious ORR. Child Health Hospital, Zibo, China; Keywords: first-line endocrine therapy, progression-free survival, objective response rate, 7 Department of Radiology, Weifang advanced breast cancer, network meta-analysis, randomized controlled trial people’s Hospital, WeiFang, China; 8Department of Oncology, Affiliated Hospital of Weifang Medical University, WeiFang, China Introduction Worldwide, breast cancer is by far the highest incidence of cancer in women and the leading cause of cancer deaths, accounting for 25% of all cancer cases (1.68 million) and 15% of cancer deaths (520,000).1,2 Approximately 30%–40% of patients diag- Correspondence: Changgang Sun nosed at early stages could develop advanced breast cancer (ABC), with ~20% 5-year Department of Oncology, Affilited survival time.3 Although ABC is not curable,4 patients can be treated with systemic Hospital of Weifang Medical University, No. 2428, Yuhe Road, Kuiwen District, therapy to control the symptoms of the disease, possibly prolonging survival time and WeiFang, ShanDong Province, China maintaining a better quality of life. Endocrine therapy, representing the standard of Tel +86 135 8369 0699 Email [email protected] care for first-line treatment,5 plays a crucial role in ABC in postmenopausal women submit your manuscript | www.dovepress.com OncoTargets and Therapy 2018:11 2647–2656 2647 Dovepress © 2018 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you http://dx.doi.org/10.2147/OTT.S165681 hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Powered by TCPDF (www.tcpdf.org) 1 / 1 Zhang et al Dovepress with hormone receptor-positive (HR+) disease.6 The first- Materials and methods line endocrine therapy consists of tamoxifen, fulvestrant, Literature and search strategy and third-generation aromatase inhibitors (AIs), such as We performed this NMA based on the Preferred Reporting anastrozole, letrozole, and exemestane.7,8 Items for Systematic Reviews and Meta-Analysis extension Third-generation AIs, with improved time to progression to NMA.21 (TTP) and better tolerability compared with tamoxifen, are We searched PubMed, EMBASE, and the Cochrane considered the standard of care for first-line treatment.9–13 Library for RCTs from inception up to November 21, Fulvestrant is a selective estrogen receptor (ER) downregu- 2017. The search for titles/abstracts was restricted to lator, which binds, blocks, and increases the degradation of English language articles. We used the Medical Subject ER proteins, inhibiting estrogen signaling.14 The 500 mg Headings/Emtree combined with free text words of breast dose of fulvestrant was approved based on data from an cancer, advanced or metastatic, randomized controlled international, randomized, double-blind, Phase III trial by the trial, and all known spellings of tamoxifen, anastrozole, name of Fulvestrant and Anastrozole Compared in Hormonal letrozole, exemestane, fulvestrant, palbociclib, and riboci- Therapy Naive Advanced Breast Cancer (FALCON). The clib. (Detailed information of search strategies in different trial compared fulvestrant 500 mg with anastrozole 1 mg databases is shown in Figures S1, S2 and S3). Addition- in patients with HR+ locally advanced or metastatic breast ally, reference lists of eligible published clinical trials cancer who had not received previous endocrine therapy.15 and meta-analyses were also tracked manually to identify In FALCON, progression-free survival (PFS) was signifi- other relevant studies. cantly longer in the fulvestrant group than in the anastrozole group (HR=0.797, 95% CI: 0.637–0.999, P=0.0486). Selection criteria Additionally, cyclin-dependent kinase (CDK)4 and CDK6 Inclusion criteria were drawn based on the framework of inhibitors have shown activity in ER-positive (ER+) breast population, intervention, comparison, outcome and study cancer in either preclinical or clinical trials.16 Palbociclib is design.22 The type of participants was HR (ER and/or For personal use only. + + the first CDK4/6 approved by the Food and Drug Admin- progesterone receptor-positive) postmenopausal women in istration (FDA) for advanced or metastatic breast cancer.17 ABC (inoperable locally ABC and metastatic breast cancer),7 Clinical data favoring palbociclib plus letrozole rather than who had not received previous treatment for the advanced letrozole alone was suggested in PALOMA-2, a double-blind disease or had not received endocrine therapy as an adjuvant Phase III study in the initial treatment of postmenopausal treatment within 12 months before study entry. The type of women with ER+, human epidermal growth factor receptor intervention was assessing the effectiveness of one of the 2-negative (HER2−) ABC.18 In terms of median PFS, the pal- following treatments as a monotherapy or in combination bociclib plus letrozole group presented a longer median PFS as the first-line treatment: tamoxifen, anastrozole, letrozole, than letrozole alone (24.8 months vs 14.5 months, HR=0.58; exemestane, fulvestrant, palbociclib, and ribociclib. The type 95% CI: 0.46–0.72; P,0.000001). Beyond that, ribociclib, OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 08-Dec-2018 of primary outcome was the ORR and PFS/TTP. The type as a small-molecule inhibitor of CDK4/6, combined with of study was RCTs that evaluated different endocrine thera- letrozole, could also extend the median PFS versus letrozole pies as the first-line therapy for treating ABC. We excluded alone (HR=0.56; 95% CI: 0.43–0.72).19 studies where endocrine therapy was used as a neoadjuvant There are many first-line endocrine therapy regimens treatment for advanced disease. Two authors (Tingting Zhang at present; however, the optimal sequence for HR+ ABC and Wenge Zhao) independently assessed the titles/abstracts is still not established. In a previous network
Load more

Recommended publications
  • ATTACHMENT 1 Barcode:3800584-02 C-570-107 INV - Investigation
    ATTACHMENT 1 Barcode:3800584-02 C-570-107 INV - Investigation - Chinese Producers of Wooden Cabinets and Vanities Company Name Company Information Company Name: A Shipping A Shipping Street Address: Room 1102, No. 288 Building No 4., Wuhua Road, Hongkou City: Shanghai Company Name: AA Cabinetry AA Cabinetry Street Address: Fanzhong Road Minzhong Town City: Zhongshan Company Name: Achiever Import and Export Co., Ltd. Street Address: No. 103 Taihe Road Gaoming Achiever Import And Export Co., City: Foshan Ltd. Country: PRC Phone: 0757-88828138 Company Name: Adornus Cabinetry Street Address: No.1 Man Xing Road Adornus Cabinetry City: Manshan Town, Lingang District Country: PRC Company Name: Aershin Cabinet Street Address: No.88 Xingyuan Avenue City: Rugao Aershin Cabinet Province/State: Jiangsu Country: PRC Phone: 13801858741 Website: http://www.aershin.com/i14470-m28456.htmIS Company Name: Air Sea Transport Street Address: 10F No. 71, Sung Chiang Road Air Sea Transport City: Taipei Country: Taiwan Company Name: All Ways Forwarding (PRe) Co., Ltd. Street Address: No. 268 South Zhongshan Rd. All Ways Forwarding (China) Co., City: Huangpu Ltd. Zip Code: 200010 Country: PRC Company Name: All Ways Logistics International (Asia Pacific) LLC. Street Address: Room 1106, No. 969 South, Zhongshan Road All Ways Logisitcs Asia City: Shanghai Country: PRC Company Name: Allan Street Address: No.188, Fengtai Road City: Hefei Allan Province/State: Anhui Zip Code: 23041 Country: PRC Company Name: Alliance Asia Co Lim Street Address: 2176 Rm100710 F Ho King Ctr No 2 6 Fa Yuen Street Alliance Asia Co Li City: Mongkok Country: PRC Company Name: ALMI Shipping and Logistics Street Address: Room 601 No.
    [Show full text]
  • Air-Insulated Medium-Voltage Switchgear Nxairs, 24Kv
    Air-insulated Medium-Voltage Switchgear NXAirS, 24kV siemens.com.cn/energy-management Air-insulated Medium-Voltage Switchgear NXA irS,24kV Contents Application Types Application Circuit-breaker switchgear NXAirS, is factory-assembled, type-tested, Types metal-enclosed and metal-clad switchgear for indoor installation accoording Typical uses to GB3906, DL404 and IEC 62271-200.. Classification Loss of service continuity category LSC2B (Metal clad) Partition class PM(Metal) Requirements Internal arc classification IAC A FLR ISC≤31.5kA Customer benefits and features arc duration=1s Technical Data Electrical data and dimensions Design data Transportation and packing Primary Solution NXAirS 24kV Design Design of switchgear Components Vacuum circuit-breaker Standards Standards, specifications, guidelines NXAirS panel Maxium rating 24kV/31.5kA/3150A 2 Air-insulated Medium-Voltage Switchgear NXA irS,24kV Air-insulated Medium-Voltage Switchgear NXAirS,24kV Contents Application Application Types Application Typical uses Classification Application Circuit-breaker switchgear NXAirS, is factory-assembled, type-tested, NXAirS circuit-breaker switchgear is used in NXAirS switchgear correspond to the following classifications according to GB3906, Types metal-enclosed and metal-clad switchgear for indoor installation accoording Typical uses substations and distribution system, mainly at the DL404 and IEC62271-200. to GB3906, DL404 and IEC 62271-200.. Classification primary distribution level. E.g. Loss of service continuity category Loss of service continuity
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • List of Main Production Facilities of ALDI Nord's Suppliers for Apparel
    List of Main Production Facilities of ALDI Nord‘s Suppliers for Apparel, Home Textiles and Shoes Version: April 2021 Produktionsstättenliste | März 2018 | Seite 0/17 Name Address Number of Employees Commodity Group Bangladesh AB Apparels Ltd. 225, Singair Road, Tetuljhora, Hemayetpur 2001 - 5000 Garment textiles Ador Composite Ltd. 1, C & B Bazar, Gilarchala, Sreepur 1001 - 2000 Garment textiles AKH Eco Apparels Ltd. 495, Balitha, Shahbelishwar, Dhamrai 5001 - 10000 Garment textiles Angshuk Ltd. 133-134, Hamayetpur, Savar 501 - 1000 Garment textiles Apparels Village Ltd. Khagan, Birulia, Savar 2001 - 5000 Garment textiles Aspire Garments Ltd. 491, Dhalla, Singair 2001 - 5000 Garment textiles B.H.I.S. Apparels Ltd. 671, Datta Para, Hossain Market, Tongi 2001 - 5000 Garment textiles Blue Planet Knitwear Ltd. Mulaid, P.O.: Tengra, Sreepur 1001 - 2000 Garment textiles Chaity Composite Ltd. Chotto Silmondi, Tripurdi, Sonargaon 5001 - 10000 Garment textiles Chantik Garments Ltd. Kumkumari, Gouripur, Ashulia, Savar 2001 - 5000 Garment textiles Chorka Textile Ltd. Kajirchor, Danga Bazar, Polash 2001 - 5000 Garment textiles Citadel Apparels Ltd. Joy Bangla Road, Kunia, K.B. Bazar, Gazipur Sadar 501 - 1000 Garment textiles Cotton Dyeing & Finishing Mills Ltd. Vill: Amtoli, Union: 10 No. Habirbari, P.O-Seedstore Bazar, P.S.-Valuka 1001 - 2000 Garment textiles Crossline Factory (Pvt) Ltd. 25, Vadam, Uttarpara, Nishatnagar, Tongi 1001 - 2000 Garment textiles Plot No. 45, 48, 49, 51 & 52; Holding No.: 3/C, Vadam, P.O.: Crossline Knit Fabrics Ltd. 1001 - 2000 Garment textiles Nishatnagar, Tongi, Gazipur-1711, Gazipur Crown Exclusive Wears Ltd. Mawna, Sreepur 2001 - 5000 Garment textiles Crown Fashion & Sweater Industries Ltd. Plot No. 781-782, Vogra, Joydebpur, Gazipur-1704 2001 - 5000 Garment textiles Denim Fashions Ltd.
    [Show full text]
  • Minimum Wage Standards in China August 11, 2020
    Minimum Wage Standards in China August 11, 2020 Contents Heilongjiang ................................................................................................................................................. 3 Jilin ............................................................................................................................................................... 3 Liaoning ........................................................................................................................................................ 4 Inner Mongolia Autonomous Region ........................................................................................................... 7 Beijing......................................................................................................................................................... 10 Hebei ........................................................................................................................................................... 11 Henan .......................................................................................................................................................... 13 Shandong .................................................................................................................................................... 14 Shanxi ......................................................................................................................................................... 16 Shaanxi ......................................................................................................................................................
    [Show full text]
  • Original Article Relationship Between ADH2 Arg47his Variation and Hepatocellular Carcinoma Susceptibility: a Meta Analysis
    Int J Clin Exp Med 2015;8(6):9543-9548 www.ijcem.com /ISSN:1940-5901/IJCEM0005251 Original Article Relationship between ADH2 Arg47His variation and hepatocellular carcinoma susceptibility: a meta analysis Shuzhen Liu1*, Yongchun Cui2*, Baohong Yang1, Ping Chai1, Zheng Su1, Qianqian Zhang1, Dejie Zheng1, Rui Li1, Guohua Yu1 1Clinical Oncology Department, Weifang People’s Hospital, Kuiwen District, Weifang, Shandong, China; 2Depart- ment of Drug Clinical Trial Institution of Shandong Cancer Hospital & Institute, Jinan, Shandong, China. *Equal contributors. Received December 26, 2014; Accepted April 28, 2015; Epub June 15, 2015; Published June 30, 2015 Abstract: Background: To further investigate the relationship between ADH2 Arg47His variation and hepatocellular carcinoma (HCC) susceptibility through a meta-analysis. Methods: The related articles were searched in PubMed, Embase and CNKI databases. And finally 518 cases and 607 controls were included in our meta-analysis Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the relationship betweenADH2 Arg47His variation and HCC risk. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. Results: Quantitative synthesis demonstrated that no significant association was found between ADH2 Arg47His variation and HCC susceptibility (His/His vs. Arg/Arg: OR=0.99, 95% CI=0.79-1.25; His/His + Arg/ His vs. Arg/Arg: OR=1.01, 95% CI=0.86-1.20; His/His vs. Arg/Arg + Arg/His: OR=0.90, 95% CI=0.74-1.11; His vs. Arg: OR=0.98, 95% CI=0.86-1.11; Arg/His vs. Arg/Arg: OR=1.05, 95% CI=0.82-1.34).
    [Show full text]
  • Long Non-Coding RNA SNHG7 Alleviates Oxygen and Glucose
    Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Long Non-Coding RNA SNHG7 Alleviates Oxygen and Glucose Deprivation/Reoxygenation-Induced Neuronal Injury by Modulating miR-9/SIRT1 Axis in PC12 Cells: Potential Role in Ischemic Stroke This article was published in the following Dove Press journal: Neuropsychiatric Disease and Treatment Tao Zhou1,* Objective: The roles of long non-coding RNA (lncRNAs) in ischemic stroke (IS) have been Shuai Wang1,* widely illustrated. Here, we focused on the function and mechanism of lncRNA SNHG7 in Kai Lu 2 IS. Chunhui Yin3 Methods: Middle cerebral artery occlusion (MCAO) was used for inducing mice to estab­ lish IS models in vivo. Oxygen and glucose deprivation/reoxygenation (OGD/R) was used 1 Department of Neurosurgery, Zibo First for treating PC12 cells to establish IS models in vitro. Relative expression of SNHG7 and Hospital, Zibo City 255200, People’s Republic of China; 2Department of miR-9 was determined by qRT-PCR. The neuronal injury was assessed by measuring relative Neurology, Liaocheng Third People’s activity of ROS, malondialdehyde (MDA) level and cell viability. Cell viability was deter­ Hospital, Liaocheng City 252000, People’s Republic of China; 3Department of mined by MTT assay. Dual-luciferase reporter (DLR) assay was employed to test the target Intervention Clinic, Weifang Hospital of of SNHG7 or miR-9. Western blot was used to determine the protein expression of SIRT1. Traditional Chinese Medicine, Weifang Apoptosis rate was measured by flow cytometry. City 261000, People’s Republic of China Results: SNHG7 was down-regulated and miR-9 was up-regulated by MCAO treatment in *These authors contributed equally to brain tissues of mice and by OGD/R treatment in PC12 cells.
    [Show full text]
  • 2013 Annual Report 2013 Annual Report Annual 2013
    China CITIC Bank Corporation Limited 2013 Annual Report 2013 Annual Report Block C, Fuhua Mansion, No. 8 Chaoyangmen Beidajie, Dongcheng District, Beijing, China Postal Code : 100027 bank.ecitic.com Important Notice The Board of Directors, the Board of Supervisors, Corporate Introduction directors, supervisors, and senior management of the Bank ensure that the information contained Founded in 1987, CITIC Bank is one of the earliest established commercial bank during China’s reform and opening up and China’s first herein does not include any false records, commercial bank participating in financing at both domestic and international financial markets. It is renowned at home and abroad for misleading statements or material omissions, brushing numerous track records in the contemporary Chinese financial history. Over the years, it has made great contributions to China’s and assume several and joint liabilities for its truthfulness, accuracy and completeness. economic development. The meeting of the Board of Directors adopted As one of the leading domestic commercial banks in terms of capital strength, CITIC Bank has grown rapidly in the wave of economic the full text and summary of the 2013 Annual development in China and has become a national commercial bank with strong comprehensive competitive edges. In July 2013, CITIC Bank Report on 27 March 2014. 14 out of the 14 ranked 47th in terms of tier-one capital and 57th in terms of total assets among the “Top 1,000 World Banks” published by British magazine The Table of Contents eligible directors attended the meeting, including Banker, ranking among the best of all Chinese commercials banks.
    [Show full text]
  • International Registration Designating India Trade Marks Journal No: 1848 , 07/05/2018 Class 1
    International Registration designating India Trade Marks Journal No: 1848 , 07/05/2018 Class 1 2727302 14/02/2014 [International Registration No. : 1195621] TRICON INTERNATIONAL LTD. Ste. 550 777 Post Oak Blvd. Houston NY 770563315 United States of America Address for service in India/Attorney address: K & S PARTNERS 109, SECTOR-44, GURGAON - 122 003, NATIONAL CAPITAL REGION, INDIA Proposed to be Used IR DIVISION Polyamide. 6985 Trade Marks Journal No: 1848 , 07/05/2018 Class 1 2729358 13/02/2014 [International Registration No. : 1195360] Clariant AG Rothausstrasse 61 CH-4132 Muttenz Switzerland Address for service in India/Attorney address: REMFRY & SAGAR REMFRY HOUSE AT THE MILLENNIUM PLAZA SEC 27, GURGAON 122009, NEW DELHI NATIONAL CAPITAL REGION INDIA Proposed to be Used IR DIVISION Chemical products used in industry, science, photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manure for agriculture; fire extinguishing compositions; tempering and soldering preparations; chemical products used for preserving foodstuffs; tanning materials; adhesives for use in industry. 6986 Trade Marks Journal No: 1848 , 07/05/2018 Class 1 2731177 24/12/2013 [International Registration No. : 1197411] TAIZHOU G-GOOD ADHESIVES CO., LTD. Shiniu Village, Yanjiang Town, Linhai, Taizhou Zhejiang CN Address for service in India/Attorney address: PARKER & PARKER CO. LLP A3 Trade Center, Stadium Circle, CG Road, Ahmedabad 380009. India Proposed to be Used IR DIVISION Gum solvents; purification preparations (clarification preparations); color-brightening chemicals for industrial purposes; plastics, unprocessed; artificial resins, unprocessed; soldering fluxes; viscose; plastisols; adhesives for industrial purposes; polyurethane. 6987 Trade Marks Journal No: 1848 , 07/05/2018 Class 1 Priority claimed from 16/12/2013; Application No.
    [Show full text]
  • Annual Report
    2019 ANNUAL REPORT (A joint stock company incorporated in the People’s Republic of China with limited liability) (H Shares Stock Code: 3866) (Preference Shares Stock Code: 4611) 2019 Contents Section I Important Notice, Contents and Definitions 3 Section II Corporate Information and Key Financial Highlights 6 Section III Chairman’s Statement 13 Section IV President’s Statement 14 Section V Business Overview 15 Section VI Discussion and Analysis of Operations 18 Section VII Significant Events 78 Section VIII Changes in Share Capital and Information on Shareholders 95 Section IX Preference Shares 105 Section X Directors, Supervisors, Senior Management and Employees 108 Section XI Corporate Governance 126 Section XII Report of the Board of Directors 150 Section XIII Report of the Board of Supervisors 157 Section XIV Independent Auditor’s Report 158 Section XV Financial Statements and Notes 165 Section XVI Unaudited Supplementary Financial Information 282 Bank of Qingdao Co., Ltd. 2 2019 Annual Report Section I Important Notice, Contents and Definitions 1. The Board of Directors, Board of Supervisors, Directors, Supervisors and senior management of the Bank assure that the information in this annual report contains no false records, misleading statements or material omissions, and severally and jointly take full responsibility for the authenticity, accuracy and completeness of the information in this annual report. 2. The proposals on the 2019 Annual Report of Bank of Qingdao Co., Ltd. and its summary were considered and approved at the 33rd meeting of the seventh session of the Board of Directors of the Bank held on 20 March 2020. There were 14 Directors eligible for attending the meeting, of whom 14 Directors attended the meeting.
    [Show full text]
  • CHINA the Church of Almighty God: Prisoners Database (1663 Cases)
    CHINA The Church of Almighty God: Prisoners Database (1663 cases) Prison term: 15 years HE Zhexun Date of birth: On 18th September 1963 Date and place of arrest: On 10th March 2009, in Xuchang City, Henan Province Charges: Disturbing social order and using a Xie Jiao organization to undermine law enforcement because of being an upper-level leader of The Church of Almighty God in mainland China, who was responsible for the overall work of the church Statement of the defendant: He disagreed with the decision and said what he believed in is not a Xie Jiao. Court decision: In February 2010, he was sentenced to 15 years in prison by the Zhongyuan District People’s Court of Zhengzhou City, Henan Province. Place of imprisonment: No. 1 Prison of Henan Province Other information: He was regarded by the Chinese authorities as a major criminal of the state and had long been on the wanted list. To arrest him, authorities offered 500,000 RMB as a reward to informers who gave tips leading to his arrest to police. He was arrested at the home of a Christian in Xuchang City, Henan Province. Based on the information from a Christian serving his sentence in the same prison, HE Zhexun was imprisoned in a separate area and not allowed to contact other prisoners. XIE Gao, ZOU Yuxiong, SONG Xinling and GAO Qinlin were arrested in succession alongside him and sentenced to prison terms ranging from 11 to 12 years. Source: https://goo.gl/aGkHBj Prison term: 14 years MENG Xiumei Age: Forty-one years old Date and place of arrest: On 14th August 2014, in Xinjiang Uyghur Autonomous Region Charges: Using a Xie Jiao organization to undermine law enforcement because of being a leader of The Church of Almighty God and organizing gatherings for Christians and the work of preaching the gospel in Ili prefecture Statement of the defendant: She claimed that her act did not constitute crimes.
    [Show full text]
  • 2020 Annual Report Contents
    (A joint stock company incorporated in the People’s Republic of China with limited liability) (H Shares Stock Code: 3866) (Preference Shares Stock Code: 4611) 2020 ANNUAL REPORT Contents Section I Important Notice, Contents and Definitions 2 Section II Corporate Information and Key Financial Highlights 5 Section III Chairman’s Statement 12 Section IV President’s Statement 14 Section V Business Overview 17 Section VI Operation Discussion and Analysis 21 Section VII Significant Events 86 Section VIII Changes in Shareholdings and Information on Shareholders 102 Section IX Preference Shares 114 Section X Directors, Supervisors, Senior Management and Employees 116 Section XI Corporate Governance 129 Section XII Report of the Board of Directors 153 Section XIII Report of the Board of Supervisors 160 Section XIV Independent Auditor’s Report 161 Section XV Financial Statements and Notes 168 Section XVI Unaudited Supplementary Financial Information 286 Bank of Qingdao Co., Ltd. 2020 Annual Report 1 Section I Important Notice, Contents and Definitions 1. The Board of Directors, Board of Supervisors, Directors, Supervisors and senior management of the Bank assure that the information in this annual report contains no false records, misleading statements or material omissions, and severally and jointly take full responsibility for the authenticity, accuracy and completeness of the information in this annual report. 2. The proposals on the 2020 Annual Report of Bank of Qingdao Co., Ltd., its summary and the results announcement were considered and approved at the 44th meeting of the seventh session of the Board of Directors of the Bank held on 30 March 2021. There were 14 Directors eligible for attending the meeting, and 14 Directors actually attended the meeting.
    [Show full text]